These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 23726889)
1. Future directions for peptide therapeutics development. Kaspar AA; Reichert JM Drug Discov Today; 2013 Sep; 18(17-18):807-17. PubMed ID: 23726889 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Lau JL; Dunn MK Bioorg Med Chem; 2018 Jun; 26(10):2700-2707. PubMed ID: 28720325 [TBL] [Abstract][Full Text] [Related]
3. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Wong MS; Sidik SM; Mahmud R; Stanslas J Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409 [TBL] [Abstract][Full Text] [Related]
4. Trends in development and approval times for new therapeutics in the United States. Reichert JM Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576 [TBL] [Abstract][Full Text] [Related]
6. Venoms as a platform for human drugs: translating toxins into therapeutics. King GF Expert Opin Biol Ther; 2011 Nov; 11(11):1469-84. PubMed ID: 21939428 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends. Kyriakopoulos S; Kontoravdi C Eur J Pharm Sci; 2013 Feb; 48(3):428-41. PubMed ID: 23262060 [TBL] [Abstract][Full Text] [Related]
8. 18th American Peptide Symposium. Peptide revolution: genomics, proteomics and therapeutics. 19-23 July 2003, Boston, MA, USA. Craik D IDrugs; 2003 Sep; 6(9):855-7. PubMed ID: 14565173 [No Abstract] [Full Text] [Related]
9. Current trends in the clinical development of peptide therapeutics. Saladin PM; Zhang BD; Reichert JM IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221 [TBL] [Abstract][Full Text] [Related]
10. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Lanthier M; Miller KL; Nardinelli C; Woodcock J Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488 [TBL] [Abstract][Full Text] [Related]
12. A need for speed: Signals in drug development. Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053 [No Abstract] [Full Text] [Related]
13. Peptide drugs to target G protein-coupled receptors. Bellmann-Sickert K; Beck-Sickinger AG Trends Pharmacol Sci; 2010 Sep; 31(9):434-41. PubMed ID: 20655603 [TBL] [Abstract][Full Text] [Related]
14. The year's new drugs & biologics 2016: Part II - Trends and highlights of an unforgettable year. Graul AI; Dulsat C; Tracy M; Cruces E Drugs Today (Barc); 2017 Feb; 53(2):117-158. PubMed ID: 28387389 [TBL] [Abstract][Full Text] [Related]
15. Molecule of the month. LBM-415. Drug News Perspect; 2005; 18(1):46. PubMed ID: 15753974 [No Abstract] [Full Text] [Related]
16. Peptides and peptide conjugates: therapeutics on the upward path. Ahrens VM; Bellmann-Sickert K; Beck-Sickinger AG Future Med Chem; 2012 Aug; 4(12):1567-86. PubMed ID: 22917246 [TBL] [Abstract][Full Text] [Related]
17. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
18. Promising targets and drugs in development for colorectal cancer. Thompson C; Leong S; Messersmith W Semin Oncol; 2011 Aug; 38(4):588-97. PubMed ID: 21810518 [TBL] [Abstract][Full Text] [Related]
19. [Clinical studies in oncology--a challenge for clinical and academic pathology]. Röcken C Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265 [No Abstract] [Full Text] [Related]